CNX-774 M SE Fudosteine significantly inhibits increases in

Fudosteine significantly inhibits increases in GRO/CINC-1 at 10-100 mg/kg

Currently it is in Phase II/III clinical trials for Hodgkin's lymphoma and advanced breast cancer

PF-06282999 is moderately bound to plasma proteins across preclinical species and humans

Smiles: CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O

CNX-774 M SE Fudosteine significantly inhibits increases inCNX 774 is a potent Btk inhibitor (IC50 < 1 nM). Recently Bruton's tyrosine kinase (BTK) , a crucial terminal kinase enzyme in the B cell antigen receptor (BCR) signaling pathway, has emerged as an attractive target for therapeutic intervention in human malignancies and autoimmune disorders. Product information CAS Number: 1202759 32 7 Molecular Weight: 499. 50 Formula: C26H22FN7O3 Chemical Name: 4 {4 [(5 fluoro 4 {[3 (prop 2